Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250771 | 0.90 | MEN1 (0.49) | MEN1KMT2AHDAC6HDAC3HDAC8 | |
| SCHEMBL4815818 | 0.85 | HDAC1 (0.48) | MEN1KMT2AHDAC6HDAC8HDAC1 | |
| SCHEMBL4820153 | 0.85 | HDAC1 (0.55) | HDAC6HDAC3HDAC8HDAC1NAMPT | |
| SCHEMBL2477216 | 0.77 | CNR1 (0.73) | MEN1KMT2AHDAC6HDAC3HDAC8 | |
| SCHEMBL674439 | 0.76 | HDAC6 (0.82) | HDAC6HDAC3HDAC8EPHX2TRPV1 | |
| SCHEMBL4810255 | 0.76 | HDAC1 (0.52) | HDAC6HDAC3HDAC8EPHX2RORC | |
| SCHEMBL4257479 | 0.74 | CNR1 (0.45) | MEN1KMT2AHDAC6HDAC1NAMPT | |
| SCHEMBL19252045 | 0.74 | MEN1 (0.66) | MEN1KMT2AMCHR1EPHX2MTOR | |
| SCHEMBL4252241 | 0.73 | SOST (0.42) | MEN1KMT2AHDAC6HDAC3HDAC8 | |
| SCHEMBL4818285 | 0.72 | SOST (0.59) | HDAC6HDAC3HDAC8HDAC1HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139547-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | claimed |
| US-7368572-B2 | Acetylene derivatives as inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | claimed |
| EP-1656348-B1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARM INC (US) | 2007-02-07 | — | — | EP | claimed |
| EP-1656348-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS, INC. (US) | 2006-05-17 | — | — | EP | claimed |
| US-20050131018-A1 | Acetylene derivatives as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-16 | — | — | US | claimed |
| WO-2005019174-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20080139547-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-7368572-B2 | Acetylene derivatives as inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1656348-B1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARM INC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1656348-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050131018-A1 | Acetylene derivatives as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2005019174-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139547-A1 | ACETYLENE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC10, HDAC2 | MEN1 3063/4885KMT2A 111/4885HDAC6 10/4885 |
| US-20050131018-A1 | Acetylene derivatives as inhibitors of histone deacetylase | HDAC1, HDAC10, HDAC2 | MEN1 3063/4885KMT2A 111/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.